Characterisation of the novel HLA-DPB1*04:02:24 allele by next-generation sequencing.

HLA-DPB1*04:02:24 differs from HLA-DPB1*04:02:01:01 by a single synonmous nucleotide substitution at position 639 G>A.

Identification of the novel HLA-C*08:291 allele by next-generation sequencing.

HLA-C*08:291, a novel HLA class I allele detected by next-generation sequencing.

A novel null HLA-B allele, B*40:510N, due to a single nucleotide deletion in exon 2.

One nucleotide deletion in codon 15 of HLA-B*40:01:02:01 results in a novel null allele, HLA-B*40:510N.

HLA-DQA1*05:115, the first DQA1 allele described with an alanine at position 59 of alpha-1 domain.

HLA-DQA1*05:115 shows an alanine at position 59 not described previously.

Characterisation of the novel HLA-DQA1*01:02:24 allele by sequencing-based typing.

HLA-DQA1*01:02:24 differs from HLA-DQA1*01:02:01:03 by one nucleotide substitution in codon 167 in exon 3.

Identification of the novel HLA-B*49:01:01:22 allele in an Indian renal transplant donor by next generation sequencing.

HLA-B*49:01:01:22 differs from HLA-B*49:01:01:01 by a single nucleotide C->G change in intron 5 at gDNA 2451.

Refining cPRA calculation to improve HLA compatibility assessment in organ transplantation: A detailed picture of the Paris waiting list.

The determination of panel reactive antibodies (cPRA) scores plays a critical role in assessing the immunological compatibility between organ transplant recipients and potential donors. Traditional cPRA methods focus on a limited number of HLA loci using physical cytotoxicity tests. However, advancements such as the Luminex single antigen (LSA) assay, which uses mean fluorescence intensity (MFI) of individualised HLA antigens for antibody evaluation, provide a foundation for a more precise assessment. We developed cPRAdictor, a novel cPRA calculation tool using a large series of HLA-type individuals in France with NGS. cPRAdictor was applied to a cohort of 5962 kidney transplant candidates in Paris. We analysed how extending the range of HLA specificities could affect cPRA values. Implementing cPRAdictor revealed and allowed quantification of the significant discrepancies in cPRA values that appeared when HLA loci C and DP, and antigen-specific antibodies were taken into account. Notably, over 43% of the immunised transplant candidates showed an increase in calculated cPRA values when considering C/DP loci and antigen-specific antibodies, negatively impacting their eligibility and prioritisation in the transplantation programme. These findings highlight the necessity of revisiting cPRA calculation methodologies to include a broader spectrum of immunological data, as more exhaustive and precise information regarding anti-HLA antibodies in patients' sera and donor and recipient HLA typing are available prospectively. This will strongly improve both accuracy and equity at the organ allocation step, especially for highly sensitised candidates for whom organ offers are very limited in number.

Characterisation of the novel KIR2DL1*00308 allele identified in a Chinese Han individual.

The novel KIR2DL1*00308 allele differs from the closest allele KIR2DL1*00302 by a single sense mutation.

The novel HLA-A*23:140 allele was identified in a Brazilian bone marrow volunteer donor.

The HLA-A*23:140 allele differs from HLA-A*23:01:01 by one nucleotide substitution (G > A), position 1968 in exon 5.

Characterisation of the novel HLA-DPA1*01:12:03 allele by sequencing-based typing.

HLA-DPA1*01:12:03 differs from HLA-DPA1*01:12:01 by one nucleotide substitution in codon 204 in exon 4.

The novel HLA class I allele HLA-C*07:02:81 differs from HLA-C*07:02:01:01 by a synonymous mutation.

HLA-C*07:02:81 differs from HLA-C*07:02:01:01 by one nucleotide substitution at position 465 (C→A) in exon 3.

Identification of nine novel HLA alleles by next-generation sequencing in individuals from India.

Nine novel HLA alleles were identified when HLA typing individuals from the Indian population.

Characterisation of two novel HLA-B alleles, B*13:194 and B*15:694 in individuals from Lithuania.

Two novel Class I HLA-B alleles HLA-B*13:194 and HLA-B*15:694 are described.

Seven new HLA alleles characterised by next-generation sequencing.

Identification of seven new HLA alleles by next-generation sequencing.

Identification of the novel HLA-DPB1*21:01:02 allele using nanopore sequencing technology.

HLA-DPB1*21:01:02 differs from HLA-DPB1*21:01:01 by one single nucleotide substitution at position 435 C>T in exon 3.

Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation.

BACKGROUND: While the detrimental role of donor-specific anti-HLA antibodies (DSAs) is well-described in the setting of hematopoietic stem cell transplantation (HSCT), few studies focus on non donor-specific ones and with controversial results. METHODS: We here report our monocenter experience on 64 adult patients receiving allogeneic HSCT from a HLA-mismatched donor between 2014 and 2022 who were tested for the presence of anti-HLA antibodies before transplant, focusing on fifteen patients with non donor-specific anti-HLA antibodies. RESULTS: The survival of patients with non donor-specific anti-HLA antibodies was inferior with respect to patients without anti-HLA antibodies and similar to patients with DSAs. Median survival of patients with non donor-specific anti-HLA antibodies was 21 months (95 % CI: 9-42) vs. 61 months (95 % CI: 17-77) among the anti-HLA antibody-negative patients, with a significantly higher mortality incidence rate ratio (3.3 times-fold greater, p = 0.01). No pattern of death causes was found CONCLUSIONS: In this monocenter series of HLA-mismatched HSCTs, impaired survival was observed in adult patients having non donor-specific anti-HLA antibodies before transplant, similar to those with DSAs. Our findings support those antibodies as a negative predictive factor even if they are not directed against the donor, thus warranting further investigation on larger cohorts.

A novel HLA-C*07 variant allele, HLA-C*07:01:01:141, identified by next-generation sequencing.

Characterisation of the novel HLA-C*07:01:01:141 allele in a 23-year-old Greek bone marrow donor.

Identification of the novel HLA-B*56:100 allele by next-generation sequencing.

HLA-B*56:100 differs from HLA-B*56:20:02 by one nucleotide substitution at codon 147.2 in exon 3.

HLA-B*07:510, a novel HLA-B allele identified in two not relative individuals.

HLA-B*07:510, a novel HLA-B allele with one exonic mutation identified in two Russian individuals.

The novel HLA-A*32 allele, HLA-A*32:01:56, identified by next generation sequencing.

HLA-A*32:01:56 differs from HLA-A-32:01:01 by a single nucleotide variation in Exon 5, codon 313.3.